FDA denies approval for Fentora non-cancer treatment

BOSTON The Food and Drug Administration has denied approval for Cephalon to market Fentora for treating pain not related to cancer, the company announced Monday.

The opioid painkiller is approved for treating breakthrough pain in some cancer patients, but the company applied for FDA approval to market it for treating chronic back pain and neuropathic pain.